Seres Therapeutics financials
$3.48−1.14%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $736.0K | $358.0K | $438.0K | $351.0K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $736.0K | $358.0K | $438.0K | $351.0K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | — | — | — | — | — | — | — | — |
| Operating income | -$21.3M | -$20.9M | -$19.4M | -$22.5M | -$24.9M | -$27.2M | -$28.8M | -$29.2M | -$28.9M | -$34.4M | -$37.0M | -$44.6M |
| Net income | $4.6M | -$19.9M | -$15.3M | $8.2M | -$19.9M | $32.7M | -$15.6M | $88.8M | -$32.9M | -$40.1M | -$41.2M | -$47.9M |
| Net margin | 622.4% | −5562.3% | −3501.1% | 2337.3% | — | — | — | — | — | — | — | — |
| Diluted EPS | $0.47 | $-2.08 | $-1.66 | $0.94 | $-2.27 | $3.75 | $-1.83 | $11.63 | $-4.34 | $-5.49 | $-6.44 | $-7.40 |
| EBITDA | -$14.8M | -$20.1M | -$18.4M | -$21.4M | -$23.8M | -$26.2M | -$27.8M | -$28.1M | -$27.2M | -$32.9M | -$35.4M | -$42.9M |
| Operating cash flow | -$22.4M | -$16.4M | -$14.7M | $2.2M | -$13.3M | $26.9M | -$38.9M | -$34.7M | -$39.8M | -$35.2M | -$47.5M | -$59.3M |
| Free cash flow | -$22.4M | -$16.4M | -$14.7M | $2.2M | -$13.5M | $26.9M | -$39.0M | -$34.8M | -$39.9M | -$35.3M | -$48.4M | -$61.1M |
| Diluted shares | 9.7M | 9.6M | 9.2M | 8.8M | 8.7M | 8.7M | 8.6M | 7.6M | 7.6M | 7.3M | 6.4M | 6.4M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $15.6M | $29.8M | $45.8M | $47.6M | $45.4M | $58.8M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $101.6M | $117.6M | $138.2M | $143.5M | $143.8M | $164.2M |
| Total liabilities | $67.1M | $91.1M | $94.0M | $99.8M | $110.8M | $113.7M |
| Shareholders' equity | $34.5M | $26.5M | $44.2M | $43.7M | $33.0M | $50.5M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology